{"id":"lenalidomide-and-dexamethasone","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Constipation"},{"rate":"10-20","effect":"Neuropathy"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide is an immunomodulatory agent that stimulates T-cell proliferation, enhances natural killer cell activity, and inhibits tumor necrosis factor-alpha production. Dexamethasone is a corticosteroid that provides additional anti-inflammatory and anti-tumor effects. Together, they work synergistically to suppress malignant plasma cell growth and enhance anti-tumor immunity in multiple myeloma.","oneSentence":"Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:21.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":"Multiple Myeloma","enrollment":1000},{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT07095452","phase":"PHASE2, PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT01297764","phase":"PHASE1, PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":"Multiple Myeloma","enrollment":1116},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Multiple Myeloma","enrollment":141},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT06353022","phase":"PHASE2","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-26","conditions":"Multiple Myeloma","enrollment":103},{"nctId":"NCT01615029","phase":"PHASE1, PHASE2","title":"Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-26","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT05438043","phase":"PHASE3","title":"A Study of Daratumumab","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-15","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06208150","phase":"PHASE3","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-22","conditions":"Multiple Myeloma","enrollment":795},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT03984097","phase":"PHASE1","title":"A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2019-07-29","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05583617","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-14","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":410},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03729804","phase":"PHASE3","title":"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-07","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT02659293","phase":"PHASE3","title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-04-26","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT04328662","phase":"","title":"A Study of Ninlaro in Real World Clinical Practice in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-18","conditions":"Multiple Myeloma, Neoplasms, Plasma Cell","enrollment":482},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":"Smoldering Plasma Cell Myeloma","enrollment":288},{"nctId":"NCT01919086","phase":"PHASE2","title":"Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-06","conditions":"Multiple Myeloma (MM)","enrollment":30},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT00378105","phase":"PHASE1, PHASE2","title":"Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2006-09","conditions":"Multiple Myeloma","enrollment":68},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT05804032","phase":"PHASE3","title":"Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"University of Heidelberg Medical Center","startDate":"2023-04-14","conditions":"Multiple Myeloma","enrollment":514},{"nctId":"NCT06348147","phase":"PHASE2","title":"Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation","status":"SUSPENDED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-07","conditions":"Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation","enrollment":39},{"nctId":"NCT06892522","phase":"PHASE1, PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-30","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT05572515","phase":"PHASE3","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-29","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":614},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT04751877","phase":"PHASE3","title":"Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-07-17","conditions":"Multiple Myeloma, Myeloma","enrollment":270},{"nctId":"NCT04113018","phase":"PHASE2","title":"Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-01-10","conditions":"Multiple Myeloma","enrollment":39},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT04447027","phase":"PHASE1","title":"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma","enrollment":26},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07297329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-12-29","conditions":"Multiple Myeloma (MM)","enrollment":292},{"nctId":"NCT02389517","phase":"PHASE2","title":"Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-03-02","conditions":"Plasma Cell Myeloma, Residual Disease","enrollment":42},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT04822337","phase":"PHASE1, PHASE2","title":"Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01562405","phase":"PHASE1","title":"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT06679101","phase":"PHASE3","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-12-16","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma","enrollment":520},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT03702725","phase":"PHASE1","title":"Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2019-08-29","conditions":"Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma","enrollment":14},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05259839","phase":"PHASE1","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-10-20","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":283},{"nctId":"NCT03180736","phase":"PHASE3","title":"Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2017-06-14","conditions":"Multiple Myeloma","enrollment":304},{"nctId":"NCT04009109","phase":"PHASE2","title":"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2020-10-21","conditions":"Myeloma, Multiple","enrollment":79},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT03290950","phase":"PHASE2","title":"A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-25","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06517017","phase":"PHASE2","title":"Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-10-09","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":40},{"nctId":"NCT04091126","phase":"PHASE1","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-12-18","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT02970747","phase":"","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-10-25","conditions":"Multiple Myeloma in Relapse","enrollment":359},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT02937571","phase":"PHASE1, PHASE2","title":"High Dose Carfilzomib for Newly Diagnosed Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-10","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT02253316","phase":"PHASE2","title":"Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-01-20","conditions":"Multiple Myeloma","enrollment":236},{"nctId":"NCT04126200","phase":"PHASE2","title":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-10-07","conditions":"Multiple Myeloma","enrollment":208},{"nctId":"NCT07025005","phase":"PHASE4","title":"Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-08-30","conditions":"Peripheral Neuropathy, Multiple Myeloma, Neoplasms","enrollment":44},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT06997081","phase":"PHASE2","title":"ERd Combination Treatment in Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-16","conditions":"Multiple Myeloma","enrollment":104},{"nctId":"NCT07210047","phase":"PHASE1, PHASE2","title":"Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients","status":"ENROLLING_BY_INVITATION","sponsor":"HuniLife Biotechnology, Inc.","startDate":"2025-08-18","conditions":"Multiple Myeloma Refractory","enrollment":21},{"nctId":"NCT04405167","phase":"PHASE1","title":"Tasquinimod for the Treatment of Relapsed or Refractory Myeloma","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT07206810","phase":"","title":"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-08-01","conditions":"Myeloma","enrollment":419},{"nctId":"NCT05145400","phase":"PHASE2","title":"Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-02-18","conditions":"Multiple Myeloma, Cancer","enrollment":50},{"nctId":"NCT07018050","phase":"PHASE2","title":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":813,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the","starting dose of 25mg on days 1-21 every 28 days (one cycle) with dose","adjustments for creatinine clearance and dose reductions. Pts will receive","low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 & 22 of each","28-day cycle with dose reductions (the weekly dose could be split over 2 days"],"phase":"phase_3","status":"active","brandName":"Lenalidomide and Dexamethasone","genericName":"Lenalidomide and Dexamethasone","companyName":"HuniLife Biotechnology, Inc.","companyId":"hunilife-biotechnology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma. Used for Multiple myeloma (newly diagnosed or relapsed/refractory), Light chain myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}